Plasmid DNA Manufacturing Market Outlook:
Plasmid DNA Manufacturing Market size was valued at USD 2.48 billion in 2025 and is expected to reach USD 14.6 billion by 2035, registering around 19.4% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of plasmid DNA manufacturing is evaluated at USD 2.91 billion.
Plasmid DNA serves as a key starting material for transient transfection and can be utilized directly as therapeutic agents. The rising boons of Plasmid DNA in treating various ailments including gene therapy, genetic engineering, and producing vaccines reflects its high plasmid DNA manufacturing market demand in the healthcare industry. Plasmid DNA is essential for the development of vaccinations, innovative genes, and cell therapies. As a result of the ongoing development of novel plasmid DNA vaccines, production processes have become more efficient and precise.
Due to plasmid’s capacity to carry large numbers of DNAs with a low risk of oncogenesis or immunogenicity, they are preferred over recombinant viruses for the development of vaccines and gene therapy. Throughout the forecast period 2025-2037, it is anticipated that growing inorganic methodologies such as key competitors in the market striving together to expand their product portfolio will propel the plasmid DNA manufacturing market expansion. For instance, In September 2022, Touchlight and Lonza announced their partnership to support the genetic medical revolution. Through this partnership, Lonza will be able to render a comprehensive and end-to-end solution for creating messengers RNA vaccines, and treatments by incorporating a distinct source of DNA.
